Professional
Added to YB: 2026-06-12
Pitch date: 2026-05-16
OLMA [bullish]
Olema Pharmaceuticals, Inc.
-29.04%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
Market Cap
$857.8M
Pitch Price
$13.74
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.88
P/E
-4.84
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Aristotle Large Cap Growth New Position: Olema Pharmaceuticals, Inc.
OLMA (new position): Clinical-stage biopharma targeting ER+/HER2- breast cancer (~70% of cases). Lead candidate Palazestrant showed favorable PFS vs peers in Phase 2, potential best-in-class. Plus early ADC platform. TAM >$20B/yr. Post-2025 raise, pro forma cash >$500M, well-funded.
Read full article (1 min)